Hospira, Inc., a global specialty pharmaceutical and medication delivery company, today announced the acquisition of worldwide rights to a biogeneric version of filgrastim and an affiliated European manufacturing facility from PLIVA Hrvatska d.o.o. (Zagreb, Croatia) , a move that will help extend Hospira's reach and vertical integration in biogenerics. Financial terms of the agreement were not disclosed.
The details can be read here.
No comments:
Post a Comment